Stuart Willson
Internal Medicine · Los Angeles, CANPI 1841262045
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,769 and has fallen 96.3% since, to $65 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$487
- Bayer$472
- AbbVie$422
- Xeris Pharmaceuticals, Inc.$322
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,707100%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 73 | $1,129 |
| Novo Nordisk | 71 | $1,046 |
| Amgen | 23 | $487 |
| Bayer | 20 | $472 |
| AbbVie | 18 | $422 |
| Xeris Pharmaceuticals, Inc. | 18 | $322 |
| GSK | 21 | $318 |
| Boehringer Ingelheim | 12 | $303 |
| Mannkind Corporation | 15 | $290 |
| Mallinckrodt Hospital Products Inc. | 10 | $181 |
| Amarin Pharma, Inc. | 9 | $176 |
| Cvrx, Inc. | 1 | $169 |
| AstraZeneca(2 entities) | 7 | $159 |
| Insulet Corporation | 8 | $155 |
| Dexcom, Inc. | 7 | $151 |
| Alvogen Inc | 4 | $98 |
| Mallinckrodt Enterprises LLC | 4 | $91 |
| Abbott | 4 | $88 |
| Corcept Therapeutics | 4 | $76 |
| Radius Health, Inc. | 3 | $75 |
| Pfizer | 3 | $71 |
| IBSA Pharma Inc. | 3 | $59 |
| Merck | 3 | $49 |
| Johnson & Johnson | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| Ascensia Diabetes Care US Inc. | 2 | $37 |
| Exact Sciences | 2 | $36 |
| BD | 1 | $28 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Ascend Therapeutics US, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,725 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 27 | $509 |
| Atorvastatin Calcium | 52 | $474 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 11 | $348 |
| Losartan Potassium | 12 | $277 |
| Pravastatin Sodium | 13 | $166 |
| Omeprazole | 13 | $136 |
| Metformin Hcl | 20 | $111 |
| Hydrochlorothiazide | 11 | $21 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.